Skip to main content

New York Certifies Verinata's Lab, Paving Way for Firm to Offer Verifi NIPD in All 50 States

NEW YORK (GenomeWeb News) – Illumina announced late Thursday that Verinata Health has received a clinical laboratory permit from the State of New York for its laboratory, allowing the company to market its Verifi non-invasive prenatal diagnostic test in the state.

As a result, the test for trisomy 21, 18, and 13 and sex chromosome abnormalities can be offered by Verinata in all 50 states. Illumina, which purchased Verinata in February, noted that Verinata's laboratory is CLIA certified and CAP accredited.

During Illumina's recent second-quarter conference call, President and CEO Jay Flatley said that it plans to obtain clearance from the US Food and Drug Administration to sell Verifi as an in vitro diagnostic test and has begun discussions with the agency on a trial design.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.